Exelixis
innovative medicines provider
Flexible on-site
The team generally works at the office, but is provided with flexible work options (e.g. option to work remotely part-time).
💼Healthcare
👥201-500
📍Alameda, California, United States
Exelixis

About Exelixis

About Exelixis
About Exelixis
About Exelixis
About Exelixis
Exelixis works is focused on discovering, developing and commercializing therapies for the treatment of cancer and other serious diseases.

What Exelixis is building

Exelixis product / service
Exelixis product / service
Exelixis product / service
Exelixis product / service
provided a solid commercial foundation allowing us to reinvigorate our research efforts, and grow our team in areas such as Drug Discovery, Clinical Development and Commercial

Technologies used at Exelixis

Back-end (2)
Front-end (1)
LinuxLinux
AWSAWS

Funding roundsIconOpenNewWindows

Total Funding

Total Funding

$379M
Last funding round type

Last funding round type

Post-IPO Equity
Company type

Company type

For Profit

Exelixis news and updates

Exelixis, Inc. partners with Sairopa

In a second deal, Exelixis entered into an exclusive clinical development and option agreement with Netherlands-based Sairopa for ADU-1805.

Dec 9, 2022 | biospace.com

Exelixis, Inc. files suit against Teva

Cancer-focused biotech Exelixis, Inc. ( NASDAQ: EXEL ) has filed another court case against Israeli drugmaker Teva Pharmaceutical Industries ( TEVA ) on allegations of patent infringement related to a generic version of the company’s kidney cancer therapy Cabometyx.

Sep 6, 2022 | seekingalpha.com

Exelixis, Inc. launches Phase III COSMIC-313 Trial hit the primary endpoint

Exelixis announced that its Phase III COSMIC-313 Trial hit the primary endpoint, demonstrating significant improvement in progression-free survival (PFS).

Jul 18, 2022 | biospace.com

Exelixis, Inc. is developing King of Prussia plot

Exelixis is presently working with Brandywine Trust Realty to develop a King of Prussia plot on Park Ave., east of 1st Ave., near the Valley Forge Casino Resort.

Jan 1, 2022 | vista.today

Exelixis, Inc. is developing next-generation version of Cabometyx

Further, Exelixis is working on a next-generation version of Cabometyx as well as other earlier-stage drugs, RBC Capital Markets analyst Gregory Renza said in a report.

Jan 1, 2022 | investors.com
See More